Sanofi-Aventis, the French drug major which is in a dilemma over a study which has found a possible
link between its blockbuster drug Lantus and cancer, has come out with more clarifications to mitigate
public concern.
The $3.45-billion drug, approved for sale in the US in 2000, was the first once-a-day form of insulin.
Following the disclosure by the study, shares of Sanofi-Aventis SA slumped the most in seven months
in Paris trading. The two-day drop knocked $10.8 billion off Sanofi's market value.
The company on Tuesday said it will convene a "roundtable of global experts" for advice on how to
proceed with a study to address concern that its Lantus diabetes drug may be tied to an increased risk
of cancer
source : http://in.biz.yahoo.com/090630/50/battey.html
link between its blockbuster drug Lantus and cancer, has come out with more clarifications to mitigate
public concern.
The $3.45-billion drug, approved for sale in the US in 2000, was the first once-a-day form of insulin.
Following the disclosure by the study, shares of Sanofi-Aventis SA slumped the most in seven months
in Paris trading. The two-day drop knocked $10.8 billion off Sanofi's market value.
The company on Tuesday said it will convene a "roundtable of global experts" for advice on how to
proceed with a study to address concern that its Lantus diabetes drug may be tied to an increased risk
of cancer
source : http://in.biz.yahoo.com/090630/50/battey.html
No comments:
Post a Comment